Chicago, ILLINOIS4 Active Studies

Diffuse Large B-Cell Lymphoma Clinical Trials in Chicago, ILLINOIS

Find 4 actively recruiting diffuse large b-cell lymphoma clinical trials in Chicago, ILLINOIS. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
1,386
Enrolling

Recruiting Diffuse Large B-Cell Lymphoma Studies in Chicago

RecruitingChicago, ILLINOISNCT06890884

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that ...

594 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingChicago, ILLINOISNCT05605899

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma....

300 participants
Kite, A Gilead Company
View Study Details
RecruitingChicago, ILLINOISNCT04792489

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractor...

248 participants
Miltenyi Biomedicine GmbH
View Study Details
RecruitingChicago, ILLINOISNCT02227251

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated cli...

244 participants
Karyopharm Therapeutics Inc
View Study Details

About Diffuse Large B-Cell Lymphoma Clinical Trials in Chicago

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.

There are currently 4 diffuse large b-cell lymphoma clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 1,386 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Kite, A Gilead Company, Miltenyi Biomedicine GmbH and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diffuse Large B-Cell Lymphoma Clinical Trials in Chicago — FAQ

Are there diffuse large b-cell lymphoma clinical trials in Chicago?

Yes, there are 4 diffuse large b-cell lymphoma clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What diffuse large b-cell lymphoma treatments are being tested?

The 4 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov